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Abstract 
Rats were intratracheally instilled with bleomycin or with silica (quartz) dust to induce lung fibrosis. Several weeks later, purified 
collagen chains (or collagen digests) were isolated from the lungs of these animals and from age-matched controls instilled intratracheally 
with saline solution, and the ratios of hydroxylysine to lysine and of the difunctional cross-links DHLNL to HLNL were quantified. 
Collagen from fibrotic lungs had significantly higher ratios of DHLNL:HLNL than did control ungs, 15.5 + 4.8 and 17.1 __+ 4.8 vs. 
2.3 + 0.5 for the silica-instilled and the bleomycin-instilled animals, respectively. The hydroxylysine:lysine ratio was significantly 
increased for the a 1(I) chain, to a value 170% of that of lung collagen from control animals, and for several of its constituent CNBr 
peptides. Lung tissue was exhaustively digested with collagenase and specific cross-linked peptides were isolated and characterized. The 
cross-linked a l ( I )x  al(I) peptide linked by the residues 87 x 16 c, with a ratio of DHLNL:HLNL of 17:1, demonstrated that the 
increased hydroxylation of the difunctional cross-links in fibrotic lung collagen could be accounted for in part by increased hydroxylation 
of the lysine residue at position 16 c of the C-terminal telopeptide of the collagen c~l(I) chain. It proved impossible to locate the 
corresponding N-terminal cross-linked fragment from c~ 1(I) × a 1(I) chains, 9 N X 930, possibly due to further eactions of this material to 
form the material referred to as poly(CB6). Isolated poly(CB6) accounted for more than half of the total a I(I)CB6 peptide xpected in 
lung collagen, and had a hydroxylysine:lysine content 2.8 times greater in bleomycin-treated animals than in their age-matched controls. 
Evidence was also found for a cross-linked oz 1(III) × a 1(1) peptide linking residue 87 from the a 1(III) chain with residue 16 c from the 
ce 1(I) chain; it also had an increased ratio of DHLNL:HLNL. We conclude that the increased hydroxylation of lysine observed in two 
different animal models of lung fibrosis occurs preferentially atthe N- and C-terminal nonhelical extension peptides of the a 1(I) collagen 
chains, and that this apparent specificity of overhydroxylation f fibrotic collagen may have important structural and pathological 
consequences. 
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1. Introduction 
Pulmonary fibrosis, a disease that results in the deposi- 
tion of excess, abnormal collagen in the lung, causes a 
decreased total lung capacity for inspired air and a stiffen- 
ing (decreased compliance) of the parenchymal tissue. 
Thus, more force is required to move a comparable volume 
of air into and out of the lung. The exact molecular basis 
underlying these pathological and physiological changes in 
either chronic disease, idiopathic pulmonary fibrosis (IPF), 
or acute fibrotic disease, adult respiratory distress syn- 
drome (ARDS), is not yet well defined. It is known that 
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there is more total collagen in fibrotic lungs than in normal 
human lungs [1,2], and that there is a relative excess of 
type I collagen with respect to type Ill in pulmonary 
fibrosis [3,4]. Data from animal experiments uggest hat 
the excess collagen in fibrotic lungs is all type I collagen, 
consistent with the relative increase in the ratio of type I to 
type III [5]. It has also been shown that the relative (and 
absolute) amount of hydroxylysine-derived collagen 
cross-links is increased in the lungs of patients with IPF 
and ARDS [6]. The relative contributions of the excess of 
total lung collagen per se, the increased relative amount of 
type I collagen, and the alterations in collagen cross-lin- 
king to the increased stiffness of fibrotic lungs is not 
known. The simplest hypothesis to explain these experi- 
mental observations i that the changes in collagen types 
and cross-linking in fibrotic lungs are both biomarkers of 
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the excess collagen deposited in these lungs. That is, one 
can hypothesize that all of the excess collagen deposited in 
fibrotic lungs is type I collagen, and that the excess of 
lysine hydroxylation giving rise to the altered cross-linking 
pattern occurs uniquely in type I collagen. 
Two well-studied models of pulmonary fibrosis in rats 
are the bleomycin model [7] and the silica model [8]. In 
both models, increased rates of collagen synthesis are 
observed. The two models differ in that in the bleomycin 
model, there is a characteristic shift in collagen types being 
synthesized to favor an excess of type I to type III. 
However, this shift does not occur in the silica model, in 
which the synthesis of both types I and type III is in- 
creased. We have also observed that the excess collagen 
laid down in the lungs of animals with pulmonary fibrosis 
[9-11] contains relatively more hydroxylysine and hydrox- 
ylysine-derived cross-links than does normal lung colla- 
gen. These changes are also observed in lungs from human 
infants and adults with fibrotic lung diseases [6,12]. Previ- 
ously we have shown that lung minces prepared from rats 
that had been intratracheally injected with bleomycin one 
week earlier synthesize collagen that is specifically over- 
hydroxylated in the lysine residues of type I, but not type 
III, collagen [13]. We also reported that the activity of the 
enzyme responsible for hydroxlyation of lysine in colla- 
gen, lysyl hydroxylase (EC 1.14.11.4) is elevated in lung 
homogenates prepared from rats administered bleomycin, 
thereby suggesting an underlying molecular mechanism 
responsible for these observations. 
The ratio of the difunctional intermolecular c oss-links 
dihydroxylysinonorleucine (DHLNL) to hydroxylysinonor- 
leucine (HLNL) is one measure of this increase in the 
hydroxylation of lysine. An increase in the ratio of 
DHLNL:HLNL is also observed in other human diseases 
or animal models that exhibit an altered content of hydrox- 
ylysine and of lysine- and hydroxylysine-derived cross- 
links. These abnormalities have been observed in human 
hypertrophic scars [14,15], in the skin of patients with 
lipoid proteinosis [16], in patients with annulo-aortic ecta- 
sia [17], and in a model in which chicken tendons are 
subjected to an increased tensile load as a result of muscle 
hypertrophy [18]. This latter model was the basis for a 
recent study [19] in which the peptides corresponding to
the two known major cross-linking sites in type I collagen, 
at the N- and C-terminal ends of the t~l(I) chains, were 
isolated and purified. One of these sites involves the 
N-terminal nonhelical lysine (or hydroxylysine) 9 N, and 
the lysine (or hydroxylysine) at position 930. The other 
site consists of the C-terminal non-helical lysine (or hy- 
droxylysine) at 16 c and the lysine (or hydroxylysine) at 
position 87. We showed that the DHLNL:HLNL ratio is 
increased in the hypertrophic tendon, and that the ratio is 
increased to the same extent in samples derived from the 
N-terminal as the C-terminal lysine aldehyde residues. 
In the current study we have extended our studies of 
lysine hydroxylation i collagen in two well studied ani- 
mal models characterized by aberrant lung collagen syn- 
thesis. We have asked whether the changes we previously 
reported [13] in the levels of lysine hydroxylation of t~ 1(I) 
chains of type I collagen found with the lung mince system 
in vitro accurately reflect alterations occurring in vivo in 
the lung collagen of rats administered bleomycin. We have 
also isolated specific cross-linked peptides from the lung 
and examined their DHLNL:HLNL ratios to better define 
the changes in lysine hydroxylation occurring at the 
telopeptides of fibrotic lung collagen. 
2. Materials and methods 
2.1. Administration of bleomycin and of silica 
25 mg of crystalline silica or 1 U of bleomycin sulfate 
(Blenoxane; a gift from Bristol Laboratories, Syracuse, 
NY) in 0.3 ml of phosphate-buffered saline was instilled 
intratracheally into the lungs of male, 175-200 g 
Sprague-Dawley rats (Bantin-Kingman, Gilroy, CA). Con- 
trol animals received phosphate-buffered saline alone. Af- 
ter two or four weeks (for the studies on difunctional 
cross-links in the bleomycin model), 4 wk (for the studies 
on difunctional cross-links in the silica model) or 6 wk (for 
the studies on hydroxylation of collagen alpha chains and 
peptides in the bleomycin model) the rats were killed and 
their lungs were removed. Lungs from several animals 
were pooled for the examination of the extent of lysine 
hydroxylation i whole collagen chains and for the charac- 
terization of cross-linked peptides; three control and four 
bleomycin animals were analyzed for the estimation of the 
extent of lysine hydroxylation i collagen-derived CNBr 
peptides, and 6 control and 7 bleomycin animals were used 
for the experiments with poly(CB6). Replicate samples of 
lungs from individual animals were used for the determina- 
tion of DHLNL:HLNL ratios in collagen-derived peptides. 
2.2. Preparation of collagen alpha chains 
Lungs lobes were washed, minced, and homogenized in 
0.5 M acetic acid. Pepsin (1% w/w; Sigma, St. Louis, 
MO) was added and the homogenate was digested for 24 h 
at 4°C. The soluble collagen was separated from the 
insoluble residue by centrifugation and the various colla- 
gen chains were separated by chromatography on carboxy- 
methylcellulose aspreviously described [20]. 
2.3. Digestion with cyanogen bromide and gel elec- 
trophoresis 
Partially purified collagen chains were dissolved in 2 ml 
of 70% formic acid. Cyanogen bromide (1.5:1, mg 
CNBr/mg collagen dry weight based upon hydroxyproline 
analysis; Sigma, St. Louis, MO) was added and the sam- 
ples were digested for four hours at 37°C. The cyanogen 
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bromide and formic acid were removed by rotary evapora- 
tion under reduced pressure. The peptides were desalted by 
dialysis and then partially purified by an initial chromatog- 
raphy step using a carboxymethylcellulose column. The 
peptides were eluted from the column using a 0.02 M 
sodium-citrate, pH 3.7, buffer containing 1 M NaC1. The 
peptides were desalted and then separated by chromatog- 
raphy on a C18 reverse phase HPLC column. A linear 
gradient of acetonitrile (0-40% over 90 min) in 0.01 M 
heptafluorobutyric a id was used to separate the peptides 
on a Vydac 218TP54 column (Separations Group, Hespe- 
ria, CA). Appropriate fractions from the Vydac runs were 
pooled. A portion of each pooled fraction was analyzed by 
gel electrophoresis: the remainder was hydrolyzed and 
analyzed by HPLC to determine hydroxylysine to lysine 
ratios. 
The identities of the collagen alpha chains purified by 
carboxymethylcellulose r the peptides in the pooled frac- 
tions from the Vydac column were confirmed by elec- 
trophoresis on polyacrylamide gels [21] in parallel with 
appropriate marker peptides. 
2.4. Preparation of cross-linked lung collagen 
Lung lobes from control, silica, and bleomycin lungs 
were washed overnight in 0.15 M NaC1 and then reduced 
with NaB3H4 . Sample sizes ranged from 0.5 to 2.5 g wet 
wt. The lungs were reduced as previously described [12], 
except hat the amount of NaB3H4 used was decreased by 
two-thirds. After reduction, the lung lobes, which in a 
normal rat lung contain about 15% collagen, were homog- 
enized in 10 ml of 4 M KSCN. The lung lobes were 
extensively extracted to remove as much non-collagenous 
material as possible. The washed preparation was then 
resuspended in collagenase digestion buffer (0.01 M CaC12, 
0.02 M Tris-HC1, pH 7.55). Type VII collagenase (Sigma) 
was dissolved in the same buffer at a concentration of 10 
U//xl. 3 U of collagenase were added per mg of lung dry 
weight before extraction, immediately after the lung had 
been heated to 65°C for 20 min and quickly cooled to 
37°C. After 8 hours, another 3U per mg (of collagen) of 
collagenase was added and the lungs were incubated for an 
additional 16 hours (a total of 24 hours). The digested lung 
lobes were spun in a microcentrifuge for 5 min. The 
supernatant was saved and used as a source of 
collagenase-digested collagen. 
2.5. Peptide purification 
Amicon M r 10000 cut-off ilters were used as an initial 
purification step as previously described [19]. The retentate 
was saved and the filtrate was centrifuged through an 
Amicon M r 3000 filter. The resulting retentate and filtrate 
were saved. Aliquots of each of these three fractions, as 
well as the unfractionated starting material, were analyzed 
for reducible cross-link and hydroxyproline content. 
2.6. HPLC separation of collagenase-derived peptides 
A Vydac C18 column (201TP54, Separations Group, 
Hesperia, CA) was used to separate the peptides from the 
collagenase digest. All buffers contained acetonitrile and 
0.01 M heptafluorobutyric a id as an ion-pairing agent: a 
modification of the method of van der Rest and Fietzek 
[22] was used. For the separation of the larger than M r 
10000 retentate fraction, buffer A contained 4% CH3CN 
and buffer B, 80% CH3CN. A linear gradient from 100% 
A to 100% B over 90 min was used. The eluate absorbance 
was monitored at 215 nm. 1-min fractions were collected, 
and an aliquot (usually 50 /xl) from each fraction was 
counted in a Beckman scintillation counter. For other 
separations, buffer B contained 40% or 60% CH3CN, 0.01 
M heptafluorobutyric acid. 
2.7. Endoproteinase Glu-C 
Some purified collagenous peptides were further di- 
gested with endoproteinase Glu-C (Sigma). Peptides were 
placed in 0.01 M sodium phosphate buffer, pH 7.8. The 
protease was added at a concentration of 5% (w/w), and 
the mixture was incubated overnight at 25°C. The digest 
was then centrifuged in a microcentrifuge. The resulting 
supernatant was chromatographed on a Vydac column. 
2.8. Analysis of hydroxylysine and difunctional cross-links 
by HPLC 
The relative content of hydroxylysine and lysine, as 
well as of the difunctional cross-links DHLNL and HLNL, 
was determined by modifications of the method of Reiser 
and Last [5]. Hydrolysates were analyzed by reverse phase 
HPLC using a Beckman C18 Ultrasphere column (0.46 × 
25 cm). An isocratic buffer (0.3% sodium dodecylsulfate, 
0.01 M sodium phosphate, pH 2.84) containing 22% n- 
propanol for hydroxylysine and lysine determination, or 
24% n-propanol for cross-link determination, was used. 
The amino acids and cross-links were detected by postcol- 
umn derivitization with o-pthalaldehyde. The fluorescent 
adducts were detected by a Hitachi F1000 fluorometer and 
quantified on a Hitachi D2000 integrator. Fractions were 
collected at 1-min intervals and their radioactivity was 
measured by liquid scintillation counting. 
2.9. Preparation of poly(CB6) 
Aliquots of CNBr digests were chromatographed on a 
BioGel A-1.5m column (5 cm × 160 cm) using Tris-HC1, 
1 M CaC1 z, pH 7.4, as eluant at a flow rate of 100 ml/hr. 
Absorbance of the effluent stream was monitored spec- 
trophotometrically at 230 nm. The void volume fractions 
were pooled and lyophilized: this material was opera- 
tionally defined as poly(CB6), based on previous reports 
by [23]. The later eluting fractions were also pooled and 
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lyophilized. Aliquots of the pooled fractions were hydro- 
lyzed and analyzed by a colorimetric assay for hydroxy- 
proline content [24]. 
2.10. Sequence analysis 
Peptides were sequenced by the University of California 
(Davis), Protein Structure Laboratory using a gas phase 
automatic sequencer. 
2.11. Preparation and characterization of polyclonal anti- 
bodies to CB6 
The purified a l(I)-derived peptide CB6 was prepared 
from CNBr digests of washed rat tail tendon by ion 
exchange chromatography and gel filtration [5]. Purity of 
the isolated peptide was assessed by gel electrophoresis 
and compositional nalysis. A goat was injected with 1-2 
mg of purified CB6 dissolved in RIBI adjuvant (RIBI 
Immunochemical Research, Hamilton, Montana) every 
three weeks. After 9 weeks blood was first collected. The 
goat was injected and bled once a month until sufficient 
quantities of antiserum (about 300 ml) were obtained. The 
antibody assay was a modification of the ELISA procedure 
described by Rennard et al. [25]. To calibrate the antiserum 
preparation, Immulon microtiter plates (Fisher, Santa Clara, 
CA) were coated with known amounts of a l(I)CB6 or 
a I(I)CB7 (to control for specificity of the antibodies) in 
20 mM carbonate buffer, pH 9.6, containing 0.02% sodium 
azide. After the plates were coated with antigen, all reagents 
were added in phosphate-buffered saline containing 0.5% 
Tween 20. Plates were washed and blocked with 1% 
bovine serum albumin in the same buffer, then antiserum 
was added. After a 4-h incubation at 37°C, the plates were 
washed and the second antibody, mouse anti-goat IgG 
conjugated to alkaline phosphatase (Pierce Chemical Co., 
Milwaukee, WI) was added and the plates were incubated 
for 3 h. After a final wash, the chromogenic substrate 
p-nitrophenyl phosphate (Sigma, St. Louis, MO) was added 
and the plates were incubated for 30 minutes. The reaction 
was stopped by the addition of 3N NaOH. The absorbance 
was then measured at 480 nm in a microtiter plate reader 
(Dynatech Model MR 600, Chantilly, VA). The ELISA 
assay was used to determine the a l(I)CB6 content of 
different fractions obtained from the chromatographic 
columns by assaying aliquots of pooled peaks containing 
known amounts of hydroxyproline. 
2.12. Statistical analysis of data 
The mean value and the standard eviation (SD) were 
calculated for each group. Groups were compared by 
Student's t-test or by ANOVA, with a value of P < 0.05 
taken to indicate a significant difference from the control 
value. 
3. Results 
We have previously reported that the hydroxylysine to
lysine ratio is increased in the o~ l(I) chain, but not in the 
o~ l(III) chain, of newly synthesized radiolabelled collagen 
from rats treated with bleomycin [13]. The present study 
was designed to determine whether a similar increase in 
hydroxylation of lysine would be found in the total colla- 
gen deposited in the lung, and to define the molecular sites 
of increased lysine hydroxylation i fibrotic lung collagen. 
3.1. Whole lung digests 
Lung tissue prepared from rats treated 4 weeks earlier 
with bleomycin or with silica, or from age matched con- 
trois instilled intratracheally with phosphate-buffered 
saline, was washed ovemight with 4 M KSCN, reduced 
with NaBH 4 to stabilize reducible cross-links, then minced 
and homogenized. Under these experimental conditions, 
whole lung hydroxyproline is increased 2- to 3-fold in 
these animal models of pulmonary fibrosis [13]. Thus, 
50-65% of the total lung collagen is newly synthesized in
response to the fibrogenic stimulus. The observed 
DHLNL:HLNL ratios were 2.3 ___ 0.5 (mean + 1 SD, n = 5) 
for the control animals, a value slightly lower than, but 
consistent with, our previously reported value [9] for 
slightly older normal control rats of a different strain 
(Wistar, as opposed to Sprague-Dawley in the current 
studies) of 3.4 + 0.1 for this ratio. There was a large 
increase observed for the DHLNL:HLNL ratio for the rats 
treated with bleomycin or with silica, to 17.1 +__ 4.8 (n = 4) 
or 15.5 + 4.8 (n = 4), respectively, as measured in the 
fraction of collagen solubilized from the lung homogenates 
by digestion with collagenase. This preparation was further 
used as the starting material for fractionation of the 
telopeptide components of the collagen chains (see below). 
3.2. Whole collagen chains 
As shown in Table 1, we found ratios of 
hydroxylysine:lysine that were not distinguishable from 
Table 1 
Hydroxylysine:lysine ratio in collagen chains from normal and 
bleomycin-instilled rats 
Collagen Hydroxylysine:lysine ratio 
chain bleomycin control 
c¢ 1(I) 0.899 0.517 1.7 
c~ 2(I) 0.506 0.416 1.2 
c~ 1(III) 0.468 0.458 1.0 
Bleomycin: 
control ratio 
Collagen was solubilized by digestion with pepsin from pooled lungs of 
rats administered bleomycin six weeks previously, or from age-matched 
control animals. Individual chains were isolated and purified by chro- 
matography on columns of carboxymethylcellulose. Hydroxylysine and 
lysine content was determined by HPLC analysis of acid hydrolysates of
aliquots from the pooled fractions containing the indicated chains. The 
observed values are consistent with those observed previously in our 
laboratory. Typically, in our laboratory the coefficient of variance 
(SD/mean) for such determinations is about 10% [9]. Identity of individ- 
ual chains was confirmed by electrophoresis onpolyacrylamide g ls. 
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control values in the isolated, purified a 1(III) chains from 
type III collagen in the lungs of rats administered 
bleomycin. We also found ratios that appeared to be 
slightly elevated over control values in the c~2(I) chains 
from type I collagen, and that were distinctly elevated 
above control values in the e l ( I )  chains from type I 
collagen. These results agree qualitatively with those we 
found earlier [13] for purified collagen chains synthesized 
in vitro by lung minces from control animals and from rats 
instilled two weeks earlier with bleomycin, although the 
relative ratio of hydroxylysine to lysine is lower (170% vs. 
570% of control values) for the total lung el ( I )  chains 
than for the newly synthesized collagen isolated from lung 
minces. We attribute this difference to the fact that the 
collagen isolated from whole lungs by pepsin treatment 
would be a mixture of collagens made before and after 
Neomycin treatment, whereas the radioactive collagen iso- 
lated in the earlier in vitro experiments with minced lungs 
reflects the composition of lung collagen that was actually 
being synthesized by the rats at the moment hey were 
killed. 
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Fig. 2. Hydroxylysine:lysine ratio in isolated cyanogen bromide peptides. 
Cyanogen bromide-derived peptides were isolated from pepsin-solubi- 
lized lung collagen from normal (solid bars) and bleomycin-treated 
(hatched bars) rats. The individual peptides were hydrolyzed and ana- 
lyzed by reversed-phase HPLC. The fluorescent adducts formed by 
post-column derivitization with o-phthalaldehyde (OPA) of hydroxyly- 
sine and lysine were quantified and their ratio is shown. An asterisk 
indicates a significant difference (P < 0.05) between peptides isolated 
from collagen from control and bleomycin-treated animals. 
3.3. Helical components of collagen 
Pepsin-solubilized collagen was treated with CNBr to 
generate specific peptides from various parts of the colla- 
gen molecules, and the resultant peptides were purified and 
isolated by cation exchange chromatography and HPLC. 
From the ot 1(I) chain we were able to isolate and charac- 
terize three peptides, c~ I(I)CB3, ce I(I)CB7, and c~ I(I)CB8, 
accounting for a combined mol. wt. of about 62 000 or 
about the middle 60% of the al( I )  chain (Fig. 1). From 
the c~2(I) chain, the peptide a2(CB4) and the large un- 
cleaved c~2(CB3-5) were isolated. These two peptides 
constitute about 90% of the c~2 chain (see Fig. 1). Four 
peptides were available for analysis of the a 1(III) chains, 
pure al(III)CB9 and mixtures of al(III)CB8 plus 
c~ I(III)CB5 and of a I(III)CB4 plus a I(III)CB5, which 
sampled the C-terminus and the middle of the a l(III) 
chain, respectively (Fig. 1), and together account for about 
53% of the entire molecule. 
The hydroxylysine:lysine ratio was higher than control 
values in all of the peptides derived from the c~ 1(I) chain 
of lung collagen from bleomycin-treated rats (Fig. 2). For 
the c~I(I)CB3 peptide, the hydroxylysine:lysine ratio was 
about 2.5 times greater in the bleomycin-treated rats than 
in the controls; the corresponding ratio for the a I(I)CB7 
and tx I(I)CB8 peptides was about 1.5. Thus, there did not 
appear to be an N-terminal to C-terminal gradient of 
hydroxylation of lysine in the helical region of the tx 1(I) 
collagen chain. The increase in the hydroxylysine:lysine 
ratio in all of the el(D-derived peptides derived from 
bleomycin-treated lungs was significantly greater than the 
control values. The ratio of hydroxylysine:lysine i  the 
2(I)-derived peptides (a  2(I)CB4 and ce 2(I)CB3-5) was 
the same in lungs from both the bleomycin-treated and 
control animals, suggesting that the apparent slight eleva- 
tion observed in the whole a 2(I) chain was not significant. 
In addition, there was no significant elevation in the 
hydroxylysine:lysine ratios observed in the cel(III) 
cyanogen bromide peptides analyzed (Fig. 2). This finding 
confirms our observation of no increase in this ratio in the 
intact a l(III) chains. 
There was no a I(1)CB6, the C-terminal CNBr peptide 
of the a l(I) chain (see Fig. 1), visible in our preparations 
from either control or bleomycin-treated animals. We have 
consistently observed this phenomenon i  whole lung col- 
lagen preparations from mature animals prepared in our 
~l( I )  0']1214151 8 I 3 I 
10 4 2 3 
o~2(I) It I I 
7 6 
J I 
I I 
(zl(III) I 3 I 7 1 6 ill 8 1 21 4 I 5 I 9 I 
Fig. 1. Cyanogen bromide peptides. The location of the ot 1(I), ot 2(1), and ot l(III) cyanogen bromide peptides derived from purified collagen chains after 
pepsin digestion. The specific peptides indicated by the shaded bars were isolated and analyzed for their hydroxylysine:lysine ratio. 
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laboratories. We believe that the apparently missing 
a I(I)CB6 monomeric peptide is present in a high molecu- 
lar weight material previously described by Light and 
Bailey [23] that appears to contain exclusively or predomi- 
nantly a I(I)CB6 (see below). 
3.4. Telopeptide components ofcollagen chains 
Clearly, we could not account for the large differences 
in DHLNL:HLNL ratio observed in whole lung digests by 
the relatively small changes in hydroxylysine:lysine ratios 
we found in the helical peptides or whole chains from 
pepsin-digested collagen. Therefore, we turned to the 
telopeptide regions of collagen. To study the extent of 
lysine hydroxylation i the non-helical N- and C-terminal 
extensions of collagen, we determined the ratio of the 
difunctional cross-links DHLNL:HLNL. Previously, in both 
the bleomycin [10] and silica [9] models, we have shown 
the ratio of DHLNL to HLNL in the whole lung tissue is 
elevated from about 3-4:1 in the normal ung to 8-9:1 (2 
wk after bleomycin instillation or four weeks after silica 
instillation). Therefore, we set out to examine the change 
in lysine hydroxylation at two specific sites of collagen 
cross-linking by attempting to isolate and characterize the 
major cross-linking sites that are well documented tooccur 
in many tissues containing type I collagen [25]. Our previ- 
ous work in tendon (which differs from lung because it 
contains only type I collagen, whereas lung contains other 
collagens, especially type III), formed the basis by which 
these two sites could be analyzed using the relatively small 
amounts of tissue available. 
Washed lung tissue was reduced with NaB3H4 (to label 
the cross-links and to stabilize them to hydrolysis) and 
then digested with collagenase [19]. The digested samples 
were size fractionated using filters that separated the resul- 
tant mixture of peptides on the basis of their mol. wt. The 
supematant after collagenase digestion was first spun 
through a nominal M r 10000 cutoff ilter. The filtrate was 
again centrifuged, this time through a nominal M r 3000 
cutoff filter. The 10K and 3 K retentate fractions were 
hydrolyzed and analyzed for their difunctional cross-link 
and hydroxyproline content. As shown in Fig. 3, the 
amount of hydroxyproline solubilized by collagenase di- 
gestion is dramatically increased in the silica lungs. De- 
spite the differences in total yield of collagen between the 
control, silica, and bleomycin lungs, the same relative 
percentage of the total hydroxyproline r covered was found 
in the 3 K and the 10 K retentate fractions for all three 
types of lung tissue examined. The amount of hydroxy- 
proline found in the l0 K and 3 K retentate fractions is 
much less than the total determined prior to digestion or in 
the whole collagenase digest. Therefore, most of the colla- 
gen was digested to small peptides as expected with 
bacterial collagenase. The cross-linked peptides, which are 
much larger than the collagenase-derived p ptides from the 
helical regions of the collagen molecule, were effectively 
3000- -F 
= 2000' 
2. 
1000, 
o 
after collagenase 10K retentate 3K retentate 
total hyp (gg) hyp (gg) hyp (gg) 
Fig. 3. Hydroxyproline content of size fractionated peptides derived from 
collagenase-treated collagen. Lung lobes from saline (control)-, silica-, 
and bleomycin-instilled lungs were reduced with NaB3H4, washed with 
4M KSCN and digested with collagenase. The digested collagen was 
centrifuged to remove residual insoluble material and the resulting super- 
natant was passed through a M r 10000 cut-off filter. The retentate was 
saved for analysis and the filtrate was then filtered through a M r 3000 
filter. An aliquot of each fraction obtained was hydrolyzed and analyzed 
for its content of 4-hydroxyproline. Saline-instilled control (solid bars), 
bleomycin-instilled (hatched bars) and silica-instilled (shaded bars) lungs 
were analyzed. 
purified from the digest by this technique. Each of the size 
fractions, however, clearly consisted of a mixture of pep- 
tides at this stage of purification. 
The size-fractionated peptide mixtures were also ana- 
lyzed for difunctional cross-links. As shown in Fig. 4 the 
ratio of DHLNL:HLNL in the 10000 M r fraction was 
increased from about 3 in the normal ung to about 12 in 
the bleomycin- and silica-instilled lungs. In the 3000 M r 
fraction, the corresponding ratio was increased to about 13 
in the bleomycin lungs and to at least 18 in the silica-in- 
stilled lungs. In some cases no HLNL was observed. In 
order to allow quantification of the ratio in the entire group 
of animals, the DHLNL:HLNL ratio was taken to be 20 in 
the samples with no detectable HLNL. In this way, statisti- 
25 
20 
15 
10 
5 
o 
10K retentate 3K retentate 
crude fraction crude fraction 
Fig. 4. DHLNL:HLNL ratio in fractions from partially purified lung 
collagen. Peptides derived from reduced, collagenase-treated lung colla- 
gen were size fractionated as described in Fig. 3. The difunctional 
cross-links DHLNL and HLNL were analyzed by reversed-phase HPLC 
and their ratio was determined. The DHLNL:HLNL ratio of the crude 
retentates i shown. Saline-instilled control (solid bars), Neomycin-in- 
stilled (hatched bars), and silica-instilled (shaded bars) lungs were ana- 
lyzed. 
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cal analyses of the data could be performed, even though 
the actual change in the ratio might be underestimated. 
To characterize the cross-linked peptide(s) found in the 
3000 M r retentate fraction, this mixture of peptides arising 
from collagenase digestion of a pool of lungs from animals 
treated with bleomycin was further purified by reverse- 
phase HPLC. Fig. 5a shows the resulting radiochromato- 
graph obtained. The fractions were pooled as shown and 
analyzed for their cross-link content. Pools 3K-I-IV and 
3K-VI contained peptides with DHLNL:HLNL ratios rang- 
ing from 4.3-6.9. The DHLNL:HLNL ratio in pool 3K-V 
was 16.8. Pool 3K-V was eluted in an analogous position 
to the cross-linked peptide 87 × 16 c that we described in 
tendon [19]; therefore, we assumed that it contained this 
specific cross-linked peptide. Pool 3K-V was treated with 
endoproteinase Glu-C, which hydrolyzes peptide bonds at 
the carboxyl side of glutamyl and aspartyl residues. The 
resulting peptides were chromatographed on a Vydac C18 
column, the results of which are shown in Fig. 5b. The 
peak 3K-V-iii was pooled and evaporated to dryness. The 
residue was sequenced on a gas phase sequenator. The 
sequence obtained is depicted in Fig. 6. As shown, the 
peptide found is the cross-linked a l ( I )×  a l(I) peptide 
linking the residues 87 and 16 c of the al( I )  chain. At 
each of the eight cycles, two major residues were found. 
The first residue of the C-terminal nonhelical extension 
was found to be phenylalanine. This result is consistent 
with the analogous peptide that we purified from rat 
tendon [19]. The molar yields of residues were also consis- 
tent with a cross-linked peptide. We found actual molar 
y ie lds  o f  (4 8 ,20 , - ,3  0 ,3 ,5 ,25 ,1  2) and  
(29,5,20,24,20,13,19,22) pmol per residue in the helical 
and non-helical peptides, respectively. 
We used lung tissue from silica-treated animals, which 
contained a much greater amount of total collagen and of 
newly synthesized collagen than did lungs from 
bleomycin-treated or control animals (cf. Fig. 3), to at- 
tempt o purify the cross-linked peptide we had previously 
found in the 10K fraction of rat tail tendon, the a 1(I) × 
cr 1(I) peptide linking the lysine (or hydroxylysine) residues 
at 9 N and 930. Fig. 5c shows the radiochromatographic 
profile of fractions obtained from the peptides present in 
the retentate fraction from the M r 10000 cutoff filter. 
Peaks were pooled as shown, and each was hydrolyzed and 
analyzed for its difunctional cross-link content. Fraction C 
contained 83% of its total radioactivity as DHLNL and 
HLNL, about 20% of the total cross-link radioactivity 
found, and had the same elution position as the peak 
containing the 9 N × 930 cross-linked peptide from tendon 
in our earlier study [19]. Fraction C was treated with 
endoproteinase Glu-C and the resulting peptides were 
chromatographed on a Vydac C18 column; the results are 
shown in Fig. 5d. Fractions were pooled, and fraction C-3 
was sequenced. The sequence obtained was not that of the 
9 N × 930 cross-linked peptide. Instead, as shown in Fig. 7, 
we found a mixture containing two peptides derived, re- 
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Fig. 5. Purification of reduced collagenase-derived cross-linked peptides. 
Radiochromatographs of collagenase-digested p ptides from NaB3H+-re - 
duced whole lung tissue after passage through the tool. wt. cut-off filters 
described in Fig. 3. Peptides in each Mr filtration were separated by 
reversed-phase HPLC using a linear acetonitrile gradient with 0.1 M 
heptafluorbutyric a id as an ion-pairing agent. Appropriate peak fractions 
were pooled; the fractions selected for further analysis are indicated by 
the bars. A. Peptides retained by the M r 3000 filter, chromatographed 
with a 4-60% linear acetonitrile gradient over 90 rain. B, Radiochro- 
matograph of pool V (Fig. 5A) treated with endoproteinase Glu-C and 
chromatographed using a 4-40% acetonitrile gradient over 90 rain. C+ 
Peptides retained by the M r 10000 filter, chromatographed with a 4-80% 
acetonitrile gradient over 90 rain. D, Radiochromatograph of pool C (Fig. 
5C) after treatment with endoproteinase GIu-C. A 4-40% acetonitrile 
gradient over 90 rain. was used for separation of the peptides. 
spectively, from the helical c~ l(III) and a 2(1) regions that 
contain the hydroxylysine at 87, and a peptide derived 
from the nonhelical C-terminal lysine (or hydroxylysine) 
16 c of the a2(I) chains. 
Thus, we found the expected cross-link 87 × 16 c from 
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gly-met-hyl-gly-his-arg-gly-phe-ser-gly-leu-asp 
6 C I 19 C 
phe-ser-phe-leu-pro-gln-pro-pm-gln-glu-lys-ala-his-asp 
Fig. 6. Sequences of a cross-linked peptide from the M r 3000 retentate 
fraction. Predicted and experimentally obtained sequences of a cross-lin- 
ked peptide derived from rat lung digested with collagenase, purified by 
size fractionation by passage through an M r 10000 and an M r 3000 filter 
(retentate), followed by chromatography on a C18 reversed-phase col- 
unto, treatment with endoproteinase GIu-C, and further purification by 
HPLC. The literature-derived sequence of the a 1(I) collagen chain [43] is 
shown as the three-letter amino acid abbreviations. The actual sequences 
obtained for the purified peptide are shown by the underlined residues. 
a 1(I) chains in the 3 K retentate fraction. The 10K fraction 
appeared to contain the analogous cross-linked peptide, but 
derived from the amino acid residues at position 87 of the 
al(I I I) and a2(I) chains. Four to six additional samples 
from control, bleomycin and silica lungs were reduced, 
washed with KSCN, digested with collagenase and cen- 
trifuged through the molecular weight filters. As shown in 
Fig. 4, the DHLNL:HLNL ratio was increased substan- 
tially in both the 3K and 10K retentate fractions from both 
the bleomycin- and silica-instilled lung tissue. The 3 K and 
10 K samples were then (separately) chromatographed on 
a vydac C18 column, and the major peak from each was 
analyzed for cross-link content (Fig. 8). The 3K vydac 
peak (which contains the type I-derived cross-link 87 × 
16 c) from the bleomycin- and silica-treated animals had a 
DHLNL:HLNL ratio about three times that of the control. 
The 10 K Vydac peak (which contains peptides containing 
the a2(I) and al(I I I) residue at 87 and the al( I )  residue 
at 16 c) also had an increased DHLNL:HLNL ratio, al- 
though not as great as the 3 K peak. Approximately the 
same percentage of the total counts eluted from the Vydac 
columns was found in the 10 K Vydac peak from the 
control lungs as was found in the lungs from the rats 
treated with either bleomycin or silica. Thus, the peptides 
isolated from fibrotic lung collagen contained cross-links 
(and, therefore, lysine residues) with significantly in- 
7 C 19 C 
ser-pbe-leu-pro-gln-pro-pro-gln-glu-lys-ala-his-asp ~tl(I) 
79 I 90 
gly-met-hyp-gly-phe-hyp-gly-met-hyl-gly-his-arg 0d(lll) 
7 C 19 C 
ser-phe-leu-pro-gln-pro-pro-gln-glu-lys-ala-his-asp ctl(I)
76 [ 89 
gly-phe-hyp-gly-thr-hyp-gly-leu-hyp-gly-phe-hyl-gly-val tx2(I)
Fig. 7. Sequences of cross-linked peptides from the M r 10000 retentate 
fraction. Sequences obtained from purified peptides from rat lung di- 
gested with collagenase, purified by size fractionation followed by chro- 
matography on a C18 reversed-phase column, treatment with endopro- 
teinase Glu-C, and further purification by HPLC. The literature-derived 
sequences of the oH(I) collagen chain [43] are shown as the three-letter 
animo acid abbreviations. The actual sequences obtained from the par- 
tially purified peptides are shown by the underlined residues. 
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Fig. 8. DHLNL:HLNL ratio in fractions from purified lung collagen. 
Peptides derived from reduced, collagenase-treated lung collagen were 
size fractionated as described in Fig. 3. The resulting peptide mixtures 
were further purified by reversed-phase HPLC on a Vydac C18 column 
using an acetonitrile gradient, and the DHLNL:HLNL ratio of the major 
peaks obtained from each fraction (Fraction V (cf. Fig. 5a) and Fraction 
C (cf. Fig. 5c)) was determined. Saline-instilled control (solid bars), 
bleomycin-instilled (hatched bars), and silica-instilled (shaded bars) lungs 
were analyzed. 
creased amounts of hydroxylation as did the comparable 
cross-linked peptides from normal ung collagen. 
3.5. High molecular weight material (poly(CB6)) 
We were unable to find the 9NX 930 cross-linked 
peptide from a l ( I )×  a l(I) as a discrete peak from the 
Vydac C 18 column, as none of the other peaks illustrated 
in Fig. 5 contained this peptide (data not shown). We 
examined the relative amount of monomeric a l(I)CB6 
peptide in CNBr digests of whole lung collagen by quanti- 
fying the ratio of a l(I)CB6 to a l(I)CB3 on polyacryl- 
amide gels after separation of the peptides by electrophore- 
sis. Since these two peptides are similar sizes, 17.4 and 
13.2 kDa, respectively, one would expect a relative stain- 
ing intensity of about 1 (i.e., CB6/CB3 = 1.3). For tissue 
prepared from lungs 4 wk after bleomycin administration, 
we found the ratio CB6/CB3 to be about 7% of the 
predicted value (0.086_ 0.07, n = 3), while for the 
matched control ungs we found the ratio to be about 6% 
of the predicted value (0.073 +__ 0.01, n = 3). The failure to 
locate the 9 N × 930 cross-linked peptide in the collagenase 
digest of whole lung collagen is consistent with the lack of 
monomeric a l(I)CB6 observed on polyacrylamide gels 
prepared from CNBr digests of the purified solubilized 
collagen chains from these lungs. Thus, we turned to an 
examination of whether the 'missing' CB6 might be pre- 
sent as poly(CB6). 
Poly(CB6) was isolated by chromatography on a Bit- 
Gel A1.5m column [23]. We quantified the total collagen- 
derived peptides in the void-volume fraction as 4-hydroxy- 
proline, and independently estimated the total type I-de- 
rived collagen by an ELISA technique using a polyclonal 
antiserum raised against he a l(I)CB6 peptide. The ab- 
sorbance of the ELISA was linear over a range of at least 
50-250 ng for a l(I)CB6. As a test of specificity we 
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determined that the antibody preparation did not react with 
purified oll(I)CB7 or al(I)CB8. Material reacting as 
a l(I)CB6 antigen comprised 85-100% of the hydroxy- 
proline content of the poly(CB6) fraction prepared from rat 
lung based upon the assumption that the poly(CB6) species 
gives an identical color yield in the ELISA as was ob- 
tained with a CB6 standard. Thus, essentially all of the 
collagenous material in this fraction was antigenically 
identical to c~ I(I)CB6, even though it was eluted from the 
Bio-Gel A1.5m column in the void volume, corresponding 
to an apparent molecular weight of greater than 1 500 000. 
The yield of poly(CB6) material from the void volume of 
the Bio-Gel column over several preparations was about 
4.8 _ 0.9% of the total 4-hydroxyproline eluted from the 
columns, corresponding to 63% of the theoretical total 
content of a l(I)CB6 in lung collagen if we assume that 
67% of the total 4-hydroxyproline in lung is present in 
type I collagen. This is a very conservative estimate of the 
correct yield, in that we are assuming for the purposes of 
this calculation that all of the 4-hydroxyproline in the lung 
is present in types I or III collagen, with no allowance for 
4-hydroxyproline content of other collagen types known to 
be present, elastin, or surfactant proteins. Thus, the actual 
yield of the total lung content of o~ I(I)CB6 in poly(CB6) 
was probably closer to 75-80% (or more) of the theoreti- 
cal in these experiments. 
We next turned to determining the hydroxylysine:lysine 
ratio of poly(CB6) in control lungs and lungs from rats 
treated with bleomycin. In the control animals this ratio 
was 0.12_ 0.04 (n = 6) whereas the corresponding value 
in the bleomycin-treated rats was 0.33 ___ 0.07 (n = 7). This 
increase was highly significant (P  < 0.0001). Thus, the 
relative ratio of hydroxylysine:lysine was about 2.8 times 
higher than control values for the a I(I)CB6 peptide, as 
contained in poly(CB6) in the lungs from the bleomycin- 
treated rats. Presumably this hydroxylysine:lysine ratio 
reflects what would have been observed for the 9 N X 930 
cross-linked peptide were we to have been able to directly 
isolate it. Thus, poly(CB6) can serve as a surrogate for the 
9Nx 930 cross-link. We could not detect difunctional 
reducible cross-links in poly(CB6); neither DHLNL nor 
HLNL was present in this fraction. 
4. Discussion 
Previous studies from many laboratories have indicated 
that collagen deposited in fibrotic tissues contains a higher 
content of hydroxylysine than does normal collagen. In the 
present study we asked whether the increased hydroxyly- 
sine content of lung collagen from rats with experimentally 
induced pulmonary fibrosis occurs randomly throughout 
the collagen molecule, or whether specific lysine residues 
are overhydroxylated. Based on previous work with chick 
tendon collagen [19] and with collagen synthesized by lung 
slices from rats administered bleomycin [13], we predicted 
that overhydroxylation f lysine residues in lung collagen 
would occur preferentially in the N- and C-terminal exten- 
sion telopeptides of the al( I )  chains of type I collagen. 
Our results are consistent with this prediction, albeit that 
we have not been able to unequivocally characterize all of 
the known major collagen cross-linking sites in lung using 
a strategy that we had previously used successfully in 
tendon. Lung is a much more complex tissue than tendon, 
containing multiple collagen types as opposed to only type 
I collagen as is found in tendon. Thus, not surprisingly, we 
found evidence for cross-links involving type III collagen, 
the other major collagen type present, as well as type I 
collagen cross-links in rat lungs. In addition, we had 
difficulty finding either the monomeric or the cross-linked 
al(I)CB6 peptide, from the C-terminal portion of the 
al( I )  chain, in lung tissue digests. Thus, we had to 
examine a surrogate for the 9 N × 930 cross-linked peptide, 
the so-called poly(CB6) fraction, to examine hydroxyly- 
sine:lysine ratios at the C-terminal end of the oz 1(I) chain. 
We first examined hydroxylysine:lysine ratios in whole 
collagen chains isolated from lung tissue. To prepare colla- 
gen from the lungs to facilitate analysis of purified mate- 
rial, we solubilized the collagen by digestion of homoge- 
nized lung tissue from saline-or bleomycin-treated animals 
with pepsin, a procedure that gives rise to tropocollagen 
containing the helical regions of the collagen molecules 
originally present in the tissue. Although this technique 
extracts only the less cross-linked (i.e., more recently 
synthesized) collagen from the tissue, that is precisely the 
fraction we wanted to analyze as it would be enriched for 
collagen synthesized after the administration of bleomycin 
6 weeks earlier. The pepsin-solubilized collagen was puri- 
fied by salt precipitation and chromatography on carboxy- 
methylcellulose to isolate the constituent collagen chains 
from the predominant collagen types (I and III) present in 
the lung tissue. Purity of the specific pooled fractions was 
evaluated by polyacrylamide g l electrophoresis. The a 1(I) 
fraction was free of visible contamination by other colla- 
gen chains (> 95% pure). The c~2(I) fraction contained a
small amount of c~l(I) (10-15% estimated), which might 
have accounted in part for the increased 
hydroxylysine:lysine ratios found in this preparation. The 
a l(III) chains contained a very small total amount of 
collagen, i.e., the yields were very low, but the material 
appeared to be free of visible contamination by other 
collagen chains. 
We digested the purified a 1(I), a 2(I), and c~ 1(III) 
collagen chains with CNBr to generate soluble peptides, 
which allowed us to isolate purified peptides correspond- 
ing to 50-90% of the total amino acid residues in the 
helical portion of the three aforementioned chains. These 
results confirmed our findings that most, if not all, of the 
increased lysine hydroxylation i the helical residues oc- 
curs in the c~ 1(I) chains of type I collagen. This result is in 
marked contrast to the general overhydroxylation f lysine 
in different collagen types and occurring randomly 
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throughout the molecules observed in certain patients with 
genetic abnormalities of collagen metabolism [26-29], 
suggesting that a more regulated process must be occurring 
in fibrotic lungs. 
We turned next to the telopeptides of collagen, and 
were able to isolate and characterize the well known 
87 × 16 c cross-link that links the ce 1(I) × c~ 1(I) chains of 
collagen. This pure cross-linked peptide showed an ap- 
proximately 4-fold increase in DHLNL:HLNL ratio in the 
lungs of rats treated with bleomycin, suggesting significant 
overhydroxylation f the 16 c teiopeptide lysine residue in 
these fibrotic lungs. This result can be compared with the 
70% increase in lysine hydroxylation occurring in the 
helical portion of the whole isolated ~ 1(I) chains in the 
lungs of the rats administered bleomycin (Table 1). We 
also attempted to isolate the other major well known 
eel(I) × c~l(I) cross-link, the 9N× 930 cross-linked pep- 
tide, by HPLC and were unsuccessful. 
It is not clear whether the existence of poly(CB6) 
precluded us from finding the cross-linked peptide 9 N × 
930 in the same way as we had done previously in tendon 
collagen [19]. The residue 930 is a helical ysine located in 
a c~I(I)CB6; however, the cross-linked peptide we did 
successfully isolate (87 × 16 c) also contains a residue 
arising from a I(I)CB6, but at position 16 in the non-heli- 
cal telopeptide xtension. In our earlier study of chick 
tendon collagen, the retentate from the 3000 cutoff filter 
also contained a peptide corresponding to the residues 
87 × 16 c. In this regard it is noteworthy that the fractions 
we analyzed in the present study do not account for all of 
the difunctional cross-links found in the lung, so there 
must be other cross-linked peptides present. They could 
have been spread out over several fractions from the 
HPLC columns, bound irreversibly to the HPLC columns, 
or not been cleaved consistently with collagenase, so that 
these additional cross-linked peptides did not form discrete 
peaks from the Vydac column. It is also noteworthy that 
we found evidence for interchain cross-linking between 
c~l(III) × al ( I )  and c~2(I) × c~l(I) of the 87 × 16 c type. 
This approach led us into the problem of finding the 
"missing" ce I(I)CB6 peptide, which seemed to be present 
as poly(CB6), first described by Light and Bailey [23] and 
later studied by Scott [30,31]. An inherent difficulty in any 
study of poly(CB6) is the lack of a molecular definition of 
this compound. Perhaps the most commonly used opera- 
tional definition of poly(CB6) has been agarose size-exclu- 
sion chromatography as described by Light and Bailey, so 
we used this functional criterion to define poly(CB6). 
Given the relatively much greater increase seen in hydrox- 
ylysine:lysine ratio for the poly(CB6) fraction than any of 
the other helical peptides, we assume that it must have 
contained part, or all, of the telopeptide region and that 
this was the locus of increased hydroxylation of lysine. 
However, this was at best a surrogate measurement for 
either the lysine residue at position 930 of the CB6 helical 
region or the lysine residue at 16 c of the telopeptide 
region; therefore, no rigorous conclusion can be drawn as 
to which of these residues was involved, nor can we rule 
out the possibility of other lysine residues from uncharac- 
terized components of this fraction contributing to our 
results. Especially noteworthy in this connection was our 
apparent inability to find or account for the 9 N telopeptide 
lysine in any of the discrete fractions we obtained from the 
HPLC column. 
Also notable were the cross-linked peptides we ob- 
served between the residues at position 87 of the ce l(III) 
and the a2(I) helical regions and the a l(I)-derived 16 c 
telopeptide. These obligatorily intermolecular c oss-links 
are of interest as they must have cross-linked a type I and 
type III collagen molecule and two type I collagen 
molecules, respectively. Such interchain difunctional 
cross-links, which have been described previously by oth- 
ers [32], suggest patterns of collagen cross-linking that 
reflect maturation of collagen subsequent to fiber forma- 
tion. 
We have also attempted toexamine collagen cross-links 
arising from maturation of DHLNL in this study. Pyridino- 
lines were present in the crude lung fractions based upon 
fluorescence assay, but considerable amounts of nonspe- 
cific fluorescence interfered with analysis in these crude 
fractions. No pyridinolines were detected in any of the 
purified peptides that were sequenced, nor did we detect 
pyridinoline fluorescence in any of the discrete peak frac- 
tions obtained from HPLC columns of the most highly 
purified collagenous material. 
We have discussed elsewhere [13,19] the apparent role 
of lysyl hydroxylase (EC 1.14.11.4) content of lung tissue 
in regulating the extent of lysine hydroxylation i  lung 
collagen. We also discussed the possibility of there being 
separate and distinct lysyl hydroxylase activities for the 
helical and telopeptide r gions of the collagen molecule, as 
suggested by Barnes [33,34]. Recent studies with cloned 
[35,36] and expressed [37] cDNAs of lysyl hydroxylase 
would seem to refute this suggestion unequivocally, and 
provide further evidence that the amount of active lysyl 
hydroxylase in a given cell regulates the extent of site- 
specific lysine hydroxylation i the collagen synthesized 
by that cell. 
What might be the significance of the increased hy- 
droxylation of lysine in the telopeptide-derived collagen 
cross-links found in this study? It is generally accepted 
[38-40] that DHLNL is a more stable cross-link than 
HLNL, because of stabilization of the initial Schiff base 
intermediate formed between allysine and lysine by enol- 
keto tautomerism. Thus, insofar as collagen cross-linking 
stabilizes the molecule against proteolytic digestion or 
mechanical breakdown in the extracellular matrix, the 
fibrotic collagen should have a higher probability of being 
incorporated into collagen fibers than does "normal" lung 
collagen. In addition, hydroxylysine r sidues in collagen 
are potential sites of glycosylation [40]. Yamauchi and 
Mechanic [39,41] have suggested that glycosylation of 
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tropocollagen may modulate subsequent cross-linking reac- 
tions of the molecule by steric hinderance of apposition of 
potential cross-linking sites due to the additional bulk 
added by the sugars. Glycosylated hydroxylysines may 
also be preferential sites for interaction of collagen with 
other macromolecules present in the extracellular matrix, 
especially proteoglycans, and probably also be preferential 
sites for recognition by cell surface receptors and other 
matrix adhesion molecules [42]. Thus, we hypothesize that 
increased lysine hydroxylation and glycosylation of colla- 
gen in the fibrotic lung may cause modifications of the 
extracellular matrix, which in turn contribute to progres- 
sion of the cellular and structural derangements character- 
istic of the lung pathology in fibrosis. If such a hypothesis 
is correct, it may suggest suitable targets for therapeutic 
intervention at later stages of the disease process than are 
targeted by current herapeutic strategies. 
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